| Understanding the Warburg effect: the metabolic requirements of cell proliferation MG Vander Heiden, LC Cantley, CB Thompson science 324 (5930), 1029-1033, 2009 | 14852 | 2009 |
| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 11962* | 2021 |
| Apoptosis in the pathogenesis and treatment of disease CB Thompson Science 267 (5203), 1456-1462, 1995 | 9767 | 1995 |
| Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death MC Wei, WX Zong, EHY Cheng, T Lindsten, V Panoutsakopoulou, ... Science 292 (5517), 727-730, 2001 | 4804 | 2001 |
| The biology of cancer: metabolic reprogramming fuels cell growth and proliferation RJ DeBerardinis, JJ Lum, G Hatzivassiliou, CB Thompson Cell metabolism 7 (1), 11-20, 2008 | 4337 | 2008 |
| The emerging hallmarks of cancer metabolism NN Pavlova, CB Thompson Cell metabolism 23 (1), 27-47, 2016 | 4219 | 2016 |
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate L Dang, DW White, S Gross, BD Bennett, MA Bittinger, EM Driggers, ... Nature 462 (7274), 739-744, 2009 | 4209 | 2009 |
| bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death LH Boise, M González-García, CE Postema, L Ding, T Lindsten, LA Turka, ... cell 74 (4), 597-608, 1993 | 4126 | 1993 |
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours T Oltersdorf, SW Elmore, AR Shoemaker, RC Armstrong, DJ Augeri, ... Nature 435 (7042), 677-681, 2005 | 3891 | 2005 |
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 P Waterhouse, JM Penninger, E Timms, A Wakeham, A Shahinian, ... Science 270 (5238), 985-988, 1995 | 3435 | 1995 |
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate PS Ward, CB Thompson Cancer cell 21 (3), 297-308, 2012 | 3069 | 2012 |
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation ME Figueroa, O Abdel-Wahab, C Lu, PS Ward, J Patel, A Shih, Y Li, ... Cancer cell 18 (6), 553-567, 2010 | 2819 | 2010 |
| Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death E Yang, J Zha, J Jockel, LH Boise, CB Thompson, SJ Korsmeyer Cell 80 (2), 285-291, 1995 | 2786 | 1995 |
| Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis RJ DeBerardinis, A Mancuso, E Daikhin, I Nissim, M Yudkoff, S Wehrli, ... Proceedings of the National Academy of Sciences 104 (49), 19345-19350, 2007 | 2653 | 2007 |
| CTLA-4 can function as a negative regulator of T cell activation TL Walunas, DJ Lenschow, CY Bakker, PS Linsley, GJ Freeman, ... Immunity 1 (5), 405-413, 1994 | 2619 | 1994 |
| Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase MA Selak, SM Armour, ED MacKenzie, H Boulahbel, DG Watson, ... Cancer cell 7 (1), 77-85, 2005 | 2158 | 2005 |
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate PS Ward, J Patel, DR Wise, O Abdel-Wahab, BD Bennett, HA Coller, ... Cancer cell 17 (3), 225-234, 2010 | 2124 | 2010 |
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms RV Parry, JM Chemnitz, KA Frauwirth, AR Lanfranco, I Braunstein, ... Molecular and cellular biology 25 (21), 9543-9553, 2005 | 2039 | 2005 |
| X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death SW Muchmore, M Sattler, H Liang, RP Meadows, JE Harlan, HS Yoon, ... Nature 381 (6580), 335-341, 1996 | 2004 | 1996 |
| Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis M Sattler, H Liang, D Nettesheim, RP Meadows, JE Harlan, M Eberstadt, ... Science 275 (5302), 983-986, 1997 | 1995 | 1997 |
